Advocates of the Pulmonary Metastasectomy in Colorectal Cancer trial describe trial design and goals, in agreement with others that such a trial is necessary to solve the question of whether or not surgery is beneficial in patients with metastatic colorectal cancer and, ultimately, to assist patients and clinical teams in deciding for or against pulmonary metastectomy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3662857 | PMC |
| http://dx.doi.org/10.1634/theoncologist.2012-0476 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Current Strategies and Future Dimensions in the Development of KRAS Inhibitors for Targeted Anticancer Therapy.
Drug Dev Res
February 2025
South University School of Pharmacy, Savannah, Giorgia, USA.
KRAS is a proto-oncogene that is found to be mutated in 15% of all metastatic cancers with high prevalence in pancreatic, lung, and colorectal cancers. Additionally, patients harboring KRAS mutations respond poorly to standard cancer therapy. As a result, KRAS is seen as an attractive target for targeted anticancer therapy.
View Article and Find Full Text PDFTransforming cancer screening: the potential of multi-cancer early detection (MCED) technologies.
Int J Clin Oncol
January 2025
Translational Research Support Section, National Cancer Center Hospital East, Chiba, Japan.
Early cancer detection substantially improves the rate of patient survival; however, conventional screening methods are directed at single anatomical sites and focus primarily on a limited number of cancers, such as gastric, colorectal, lung, breast, and cervical cancer. Additionally, several cancers are inadequately screened, hindering early detection of 45.5% cases.
View Article and Find Full Text PDFAn investigation of antiproliferative and antioxidant properties of crude extracts from Sedum nicaeense All. (Crassulaceae).
Pak J Pharm Sci
January 2025
Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan.
This study evaluated the antioxidant and antiproliferative effects of aqueous, ethanolic and methanolic extracts of Sedum nicaeense flowers and leaves. The MTT assay assessed cytotoxicity against colorectal cancer cells (Caco-2, HCT-116), breast cancer cells (T47D, MCF-7) and normal fibroblasts (MRC-5), while the ferric-reducing antioxidant power (FRAP) assay measured antioxidant capacity. Essential oils from flowers and leaves were analyzed using gas chromatography-mass spectrometry (GC-MS).
View Article and Find Full Text PDFAtractylenolide I (ATL-I) can interfere with Colorectal cancer (CRC) cell proliferation by changing apoptosis, glucose metabolism and other behaviors, making it an effective drug for inhibiting CRC tumor growth. In this paper, we investigated the interactions between ATL-I and Keratin 7 (KRT7), a CRC-specific marker, to determine the potential pathways by which ATL-I inhibits CRC development. The KRT7 expression level in CRC was predicted online using the GEPIA website and then validated.
View Article and Find Full Text PDFTargeting KRAS: from metabolic regulation to cancer treatment.
Mol Cancer
January 2025
Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing, 100191, China.
The Kirsten rat sarcoma viral oncogene homolog (KRAS) protein plays a key pathogenic role in oncogenesis, cancer progression, and metastasis. Numerous studies have explored the role of metabolic alterations in KRAS-driven cancers, providing a scientific rationale for targeting metabolism in cancer treatment. The development of KRAS-specific inhibitors has also garnered considerable attention, partly due to the challenge of acquired treatment resistance.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!